Eiger BioPharma CFO resigns; appoints CRO amid Chapter 11 bankruptcy

Eiger BioPharmaceuticals, Inc.

CFO William G. Kachioff resigned effective April 29, 2024, as company restructures under Chapter 11.
Board appointed Douglas Staut (Alvarez & Marsal) as Chief Restructuring Officer effective April 19, 2024.
Company in Chapter 11 bankruptcy (Case 24-80040); relying on A&M for financial and accounting functions.
Company warns trading in its securities is highly speculative and may result in total loss for holders.

item 5.02 item 7.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

William G. Kachioff

Chief Financial Officer

Eiger BioPharmaceuticals, Inc.

Effective: 2024-04-29
Filed: May 2, 2024, 7:59 PM ET

On April 26, 2024, William G. Kachioff notified Eiger BioPharmaceuticals, Inc. (the “ Company ”) of his resignation as the Company’s Chief Financial Officer, to be effective April 29, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

William G. Kachioff resigned as Chief Financial Officer at Eiger BioPharmaceuticals, Inc..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

On April 26, 2024, William G. Kachioff notified Eiger BioPharmaceuticals, Inc. (the “ Company ”) of his resignation as the Company’s Chief Financial Officer, to be effective April 29, 2024.

View on SEC.gov

Source: SEC EDGAR

accession 0001193125-24-129415

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.